[HTML][HTML] The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic
One year into the global COVID-19 pandemic, the focus of attention has shifted to the
emergence and spread of SARS-CoV-2 variants of concern (VOCs). After nearly a year of …
emergence and spread of SARS-CoV-2 variants of concern (VOCs). After nearly a year of …
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
Many nations are pursuing the rollout of SARS-CoV-2 vaccines as an exit strategy from
unprecedented COVID-19-related restrictions. However, the success of this strategy relies …
unprecedented COVID-19-related restrictions. However, the success of this strategy relies …
[HTML][HTML] Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Vaccination elicits immune responses capable of potently neutralizing SARS-CoV-2.
However, ongoing surveillance has revealed the emergence of variants harboring mutations …
However, ongoing surveillance has revealed the emergence of variants harboring mutations …
[HTML][HTML] Antibody evasion by the P. 1 strain of SARS-CoV-2
Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates …
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates …
Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine
V Oberhardt, H Luxenburger, J Kemming, I Schulien… - Nature, 2021 - nature.com
SARS-CoV-2 spike mRNA vaccines,–mediate protection from severe disease as early as ten
days after prime vaccination, when neutralizing antibodies are hardly detectable,–. Vaccine …
days after prime vaccination, when neutralizing antibodies are hardly detectable,–. Vaccine …
Neutralizing activity of BNT162b2-elicited serum
Variant SARS-CoV-2 and BNT162b2 Vaccine How well do serum samples obtained from
persons injected with the BNT162b2 vaccine neutralize the P. 1, B. 1.1. 7, and B. 1.135 …
persons injected with the BNT162b2 vaccine neutralize the P. 1, B. 1.1. 7, and B. 1.135 …
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
T Schmidt, V Klemis, D Schub, J Mihm, F Hielscher… - Nature medicine, 2021 - nature.com
Heterologous priming with the ChAdOx1 nCoV-19 vector vaccine followed by boosting with
a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in …
a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in …
Escape of SARS-CoV-2 501Y. V2 from neutralization by convalescent plasma
SARS-CoV-2 variants of concern (VOC) have arisen independently at multiple locations,
and may reduce the efficacy of current vaccines that target the spike glycoprotein of SARS …
and may reduce the efficacy of current vaccines that target the spike glycoprotein of SARS …
[HTML][HTML] Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees.
The emergence of SARS-CoV-2 variants highlighted the need to better understand adaptive
immune responses to this virus. It is important to address whether also CD4+ and CD8+ T …
immune responses to this virus. It is important to address whether also CD4+ and CD8+ T …
mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status
While mRNA vaccines are proving highly efficacious against SARS-CoV-2, it is important to
determine how booster doses and prior infection influence the immune defense they elicit …
determine how booster doses and prior infection influence the immune defense they elicit …